# FDA Announces Recall of Cetirizine Tablets

Tablets contaminated with ulcer medication pose 'life-threatening' risks.

- **Source:** [Fast Company](https://www.fastcompany.com)
- **Published:** 2026-07-22
- **Original article:** <https://www.fastcompany.com/91577805/cetirizine-recall-antihistamine-tablets-life-threatening-fears>
- **On Brifing:** https://brifing.si/s/e5781886-9639-43d4-8aeb-2ec90fd980e1

## Critical Warning from FDA

The FDA has announced that Cetirizine tablets produced by Unique Pharmaceutical Laboratories may be contaminated with a drug used to treat ulcers. This poses serious health risks, especially for individuals sensitive to the ingredients.

## Risk of Cross-Contamination

The potential contamination of the tablets with ulcer medication could lead to severe side effects, including life-threatening reactions. The FDA has warned the public to avoid using these tablets.

## Caution for Sensitive Individuals

Individuals with sensitivities to drug ingredients may experience severe allergic reactions and other health issues due to cross-contamination. The FDA strongly advises against the use of these tablets for such individuals.

## Manufacturer and Product

Cetirizine tablets, produced by Unique Pharmaceutical Laboratories, are commonly used for allergy treatment. However, they have now been recalled due to the risk of contamination with ulcer medication.

## FDA Takes Action

The FDA swiftly issued a public warning against the use of these tablets to protect public health. They have also initiated the recall process for the contaminated product.

## Protecting Public Health

This recall is a crucial step in safeguarding public health and preventing potential risks. The FDA may impose stricter regulations on manufacturers to avoid similar incidents in the future.

## Sources covering this story

- https://www.fastcompany.com/91577805/cetirizine-recall-antihistamine-tablets-life-threatening-fears — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._
